Business & Regulation

Sitting Down With... Ajaz Hussain, President, National Institute for Pharmaceutical Technology and Education, Minnesota, USA.

Will President Trump’s prices plan deliver for Americans patients?

Pharma TV ads are getting longer, less humorous and more nostalgic — while containing fewer facts.

Concerns abound that post-Brexit border delays could turn the UK into a “second tier state for pharmaceutical imports.”

Regulators step in to stop stem cell clinics from marketing unproven therapies.

The Trump Administration’s plans to move Medicare Part B drugs into the Part D system would mean additional delays and cost barriers for patients.

Biosimilars had their big break in the US in 2015, but three years later biosimilars are still struggling to make a mark.

Artificial intelligence could have a huge impact on drug discovery.

Initially, The American College of Rheumatology was cautious about biosimilars, but times have changed.

Pharmacy students take medicine safety lessons to school classrooms.